<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jah310075" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="pmc-domain-id">1888</journal-id><journal-id journal-id-type="pmc-domain">jaha</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11935617</article-id><article-id pub-id-type="pmcid-ver">PMC11935617.1</article-id><article-id pub-id-type="pmcaid">11935617</article-id><article-id pub-id-type="pmcaiid">11935617</article-id><article-id pub-id-type="pmid">39248265</article-id><article-id pub-id-type="doi">10.1161/JAHA.124.035269</article-id><article-id pub-id-type="publisher-id">JAH310075</article-id><article-id pub-id-type="other">JAHA/2024/035269</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Coronary Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Clopidogrel Versus Aspirin as Chronic Maintenance Antiplatelet Monotherapy in Patients After Percutaneous Coronary Intervention With Chronic Kidney Disease: A Post Hoc Analysis of the <styled-content style="fixed-case" toggle="no">HOST</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">EXAM</styled-content> Trial</article-title><alt-title alt-title-type="right-running-head"><styled-content style="fixed-case" toggle="no">CKD</styled-content> Subgroup Analysis of the <styled-content style="fixed-case" toggle="no">HOST</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">EXAM</styled-content> Trial</alt-title><alt-title alt-title-type="left-running-head">Kang et&#160;al</alt-title></title-group><contrib-group><contrib id="jah310075-cr-0001" contrib-type="author"><name name-style="western"><surname>Kang</surname><given-names initials="J">Jeehoon</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9078-2231</contrib-id><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310075-note-0001" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib id="jah310075-cr-0002" contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="SH">Sang&#8208;Hyeon</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8453-4146</contrib-id><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310075-note-0001" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib id="jah310075-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Park</surname><given-names initials="KW">Kyung Woo</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2432-4432</contrib-id><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310075-note-0002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><address><email>kwparkmd@snu.ac.kr</email></address></contrib><contrib id="jah310075-cr-0004" contrib-type="author" corresp="yes"><name name-style="western"><surname>Koo</surname><given-names initials="BK">Bon&#8208;Kwon</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8188-3348</contrib-id><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310075-note-0002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><address><email>bkkoo@snu.ac.kr</email></address></contrib><contrib id="jah310075-cr-0005" contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="H">Huijin</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-5930-2705</contrib-id><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310075-cr-0006" contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="M">Minju</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0748-287X</contrib-id><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310075-cr-0007" contrib-type="author"><name name-style="western"><surname>Hwang</surname><given-names initials="D">Doyeon</given-names></name><degrees>MD</degrees><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310075-cr-0008" contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="HM">Han&#8208;Mo</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1548-2351</contrib-id><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310075-cr-0009" contrib-type="author"><name name-style="western"><surname>Chae</surname><given-names initials="IH">In&#8208;Ho</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1644-2105</contrib-id><xref rid="jah310075-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jah310075-cr-0010" contrib-type="author"><name name-style="western"><surname>Shin</surname><given-names initials="WY">Won&#8208;Yong</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1517-7189</contrib-id><xref rid="jah310075-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jah310075-cr-0011" contrib-type="author"><name name-style="western"><surname>Oh</surname><given-names initials="JH">Ju Hyeon</given-names></name><degrees>MD, PhD</degrees><xref rid="jah310075-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jah310075-cr-0012" contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="YH">Yong Hoon</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9669-3598</contrib-id><xref rid="jah310075-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="jah310075-cr-0013" contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="TH">Tae&#8208;Ho</given-names></name><degrees>MD, PhD</degrees><xref rid="jah310075-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="jah310075-cr-0014" contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="BS">Bum Soo</given-names></name><degrees>MD, PhD</degrees><xref rid="jah310075-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="jah310075-cr-0015" contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="JK">Jung&#8208;Kyu</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0016-0747</contrib-id><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310075-cr-0016" contrib-type="author"><name name-style="western"><surname>Shin</surname><given-names initials="ES">Eun&#8208;Seok</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9169-6968</contrib-id><xref rid="jah310075-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="jah310075-cr-0017" contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="HS">Hyo&#8208;Soo</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0847-5329</contrib-id><xref rid="jah310075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jah310075-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine, Cardiovascular Center</named-content>
<institution>Seoul National University Hospital</institution>
<city>Seoul</city>
<country country="KR">South Korea</country>
</aff><aff id="jah310075-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Seoul National University Bundang Hospital</institution>
<city>Seongnam</city>
<country country="KR">South Korea</country>
</aff><aff id="jah310075-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Soonchunhyang University Cheonan Hospital</institution>
<city>Cheonan</city>
<country country="KR">South Korea</country>
</aff><aff id="jah310075-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology, Samsung Changwon Hospital</named-content>
<institution>Sungkyunkwan University School of Medicine</institution>
<city>Changwon</city>
<country country="KR">South Korea</country>
</aff><aff id="jah310075-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Kangwon National University School of Medicine</institution>
<city>Chuncheon</city>
<country country="KR">South Korea</country>
</aff><aff id="jah310075-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Dong&#8208;A University Hospital</institution>
<city>Busan</city>
<country country="KR">South Korea</country>
</aff><aff id="jah310075-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine, Kangbuk Samsung Hospital</named-content>
<institution>Sungkyunkwan University</institution>
<city>Seoul</city>
<country country="KR">South Korea</country>
</aff><aff id="jah310075-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Ulsan University Hospital</institution>
<city>Ulsan</city>
<country country="KR">South Korea</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence to: Kyung Woo Park, MD, PhD, MBA and Bon&#8208;Kwon Koo, MD, PhD, Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital and Seoul National University College of Medicine, 101 Daehak&#8208;ro, Jongro&#8208;gu, Seoul 03080, Republic of Korea. Email: <email>kwparkmd@snu.ac.kr</email> and <email>bkkoo@snu.ac.kr</email><break/></corresp><fn fn-type="equal" id="jah310075-note-0001"><label>*</label><p>J. Kang and S.&#8208;H. Park contributed equally.</p></fn><fn fn-type="equal" id="jah310075-note-0002"><label>&#8224;</label><p>K. W. Park and B.&#8208;K. Koo contributed equally as co&#8208;corresponding authors.</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="collection"><day>17</day><month>9</month><year>2024</year></pub-date><volume>13</volume><issue seq="60">18</issue><issue-id pub-id-type="pmc-issue-id">485141</issue-id><issue-id pub-id-type="doi">10.1002/jah3.v13.18</issue-id><elocation-id>e035269</elocation-id><history><date date-type="received"><day>29</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>08</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>26</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-26 11:25:33.990"><day>26</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JAH3-13-e035269.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JAH3-13-e035269.pdf"/><abstract><sec id="jah310075-sec-0001"><title>Background</title><p>Clopidogrel monotherapy improved clinical outcomes compared with aspirin monotherapy during a chronic maintenance period in patients who underwent coronary stenting in the HOST&#8208;EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis&#8211;Extended Antiplatelet Monotherapy) trial. However, it is uncertain whether the beneficial effect of clopidogrel over aspirin is different according to the renal function.</p></sec><sec id="jah310075-sec-0002"><title>Methods and Results</title><p>We conducted a post hoc analysis of the HOST&#8208;EXAM trial. Chronic kidney disease (CKD) was defined as baseline estimated glomerular filtration rate &lt;60&#8201;mL/min per 1.73&#8201;m<sup>2</sup>. The primary end point was a composite of all&#8208;cause death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and Bleeding Academic Research Consortium bleeding type &#8805;3, during the 2&#8208;year follow up. Among the 5438 patients enrolled in the HOST&#8208;EXAM trial, 4844 patients (mean age, 63.3&#177;10.6&#8201;years; 74.9% men) with a baseline creatinine value were analyzed in this study. A total of 508 (10.5%) patients had CKD, who were at higher risk of the primary end point compared with those without CKD (hazard ratio [HR], 2.01 [95% CI, 1.51&#8211;2.67]). Clopidogrel monotherapy was associated with a lower rate of the primary end point in both patients with CKD (HR, 0.74 [95% CI, 0.44&#8211;1.25]) and patients without CKD (HR, 0.71 [95% CI, 0.56&#8211;0.91]). No significant interaction was observed between the treatment effect and CKD status (<italic toggle="no">P</italic> for interaction=0.889).</p></sec><sec id="jah310075-sec-0003"><title>Conclusions</title><p>During the chronic maintenance period after coronary stenting, the risk of thrombotic and bleeding events was significantly higher in patients with CKD compared with those without CKD. There was no statistical difference in the treatment effect of clopidogrel monotherapy in those with versus without CKD.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah310075-kwd-0001">aspirin</kwd><kwd id="jah310075-kwd-0002">chronic kidney disease</kwd><kwd id="jah310075-kwd-0003">clopidogrel</kwd><kwd id="jah310075-kwd-0004">percutaneous coronary intervention</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Secondary Prevention</kwd><kwd>Percutaneous Coronary Intervention</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Patient&#8208;Centered Clinical Research Coordinating Center</funding-source><award-id>HI19C0481</award-id><award-id>HC19C0305</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="11"/><word-count count="6100"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>17 September 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:28.11.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jah310075-ntgp-0001"><fn id="jah310075-note-0003"><p>This manuscript was sent to Nadia R. Sutton, MD, MPH, Associate Editor, for review by expert referees, editorial decision, and final disposition.</p></fn><fn id="jah310075-note-0004"><p>Supplemental Material is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.035269" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.035269</ext-link>
</p></fn><fn id="jah310075-note-0005"><p>For Sources of Funding and Disclosures, see page 10.</p></fn></fn-group></notes></front><body id="jah310075-body-0001"><def-list list-content="abbreviations" id="jah310075-dl-0001"><title>Nonstandard Abbreviations and Acronyms</title><def-item><term id="jah310075-li-0001">CAPRIE</term><def id="jah310075-li-0002"><p>Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events</p></def></def-item><def-item><term id="jah310075-li-0003">COMPASS</term><def id="jah310075-li-0004"><p>Cardiovascular Outcomes for People Using Anticoagulation Strategies</p></def></def-item><def-item><term id="jah310075-li-0005">CREDO</term><def id="jah310075-li-0006"><p>Clopidogrel for the Reduction of Events During Observation</p></def></def-item><def-item><term id="jah310075-li-0007">EVENT</term><def id="jah310075-li-0008"><p>Evaluation of Drug&#8208;Eluting Stents and Ischemic Events</p></def></def-item><def-item><term id="jah310075-li-0009">HOST&#8208;EXAM</term><def id="jah310075-li-0010"><p>Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis&#8211;Extended Antiplatelet Monotherapy</p></def></def-item><def-item><term id="jah310075-li-0011">PROMETHEUS</term><def id="jah310075-li-0012"><p>Prasugrel or Clopidogrel in Patients With Acute Coronary Syndromes at High Thrombotic Risk</p></def></def-item></def-list><p>
<boxed-text position="anchor" content-type="box" id="jah310075-blkfxd-0001" orientation="portrait"><caption><title>Clinical Perspective</title></caption><sec id="jah310075-sec-0006"><title>What Is New?</title><p>
<list list-type="bullet" id="jah310075-list-0001"><list-item id="jah310075-li-0013"><p>In this post hoc analysis of the HOST&#8208;EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis&#8211;Extended Antiplatelet Monotherapy) trial, the risk of thrombotic and bleeding events was significantly higher in patients with chronic kidney disease compared with those without chronic kidney disease.</p></list-item><list-item id="jah310075-li-0014"><p>The clinical benefits of clopidogrel monotherapy were not statistically different according to renal function.</p></list-item></list>
</p></sec><sec id="jah310075-sec-0007"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah310075-list-1001"><list-item id="jah310075-li-1013"><p>Clopidogrel may be preferred over aspirin for long term secondary prevention regardless of baseline renal function.</p></list-item></list>
</p></sec></boxed-text>
</p><p>Chronic kidney disease (CKD) is a well&#8208;known risk factor for cardiovascular morbidity and death due to its association with increased thrombotic and bleeding adverse events.<xref rid="jah310075-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="jah310075-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jah310075-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> The increased risk of hemostatic complications with opposite characteristics can be explained by dysfunction of platelets and the enzymatic coagulation cascade in patients with CKD.<xref rid="jah310075-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Therefore, the optimal lifelong antiplatelet therapy of choice is of paramount importance in patients with CKD who receive percutaneous coronary intervention (PCI).</p><p>Recently, the HOST&#8208;EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis&#8211;Extended Antiplatelet Monotherapy) trial reported the superiority of clopidogrel over aspirin as long&#8208;term monotherapy for secondary prevention after PCI with drug&#8208;eluting stents.<xref rid="jah310075-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Clopidogrel monotherapy reduced both thrombotic and bleeding risk compared with aspirin monotherapy.<xref rid="jah310075-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> However, it is unknown whether these beneficial effects are maintained in patients with decreased renal function and whether any interaction exists between treatment effect and glomerular filtration rate. In this post hoc subgroup analysis of the HOST&#8208;EXAM cohort, we assessed the treatment effects of clopidogrel versus aspirin monotherapy according to the renal function.</p><sec sec-type="methods" id="jah310075-sec-0008"><title>METHODS</title><p>The HOST&#8208;EXAM trial is planning to continue follow&#8208;up until 2025. No individual participant data will be available before this. Any relevant inquiries should be sent to the corresponding author.</p><sec id="jah310075-sec-0009"><title>Trial Design and Population</title><p>This study was a post hoc analysis of the HOST&#8208;EXAM trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02044250">NCT02044250</ext-link>), which was an investigator&#8208;initiated, randomized, multicenter, prospective, open&#8208;label trial conducted at 37 study sites in South Korea. The trial design has been reported previously.<xref rid="jah310075-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Patients aged &#8805;20&#8201;years who maintained aspirin plus any P2Y<sub>12</sub> inhibitor without any clinical events for 6 to 18&#8201;months after undergoing successful PCI with drug&#8208;eluting stents were eligible for this study. Key exclusion criteria were patients with known hypersensitivity or contraindications for clopidogrel or those who could not change their current antiplatelet agents. Patients who met all the inclusion criteria and none of the exclusion criteria were randomized 1:1 to a clopidogrel (75&#8201;mg once daily) or aspirin (100&#8201;mg once daily) arm as a single maintenance antiplatelet therapy. Other antiplatelet agents were not permitted to be used. Patients were followed up at 12 and 24&#8201;months after randomization. The trial protocol was approved by the institutional review board at each participating site, and all patients were required to provide written informed consent at the time of enrollment and randomization.</p></sec><sec id="jah310075-sec-0010"><title>Clinical Outcomes</title><p>The primary end point was defined as a composite of all&#8208;cause death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and major bleeding complications, defined as Bleeding Academic Research Consortium type 3 or 5 bleeding, during the 24&#8208;month follow&#8208;up period. The secondary end points included the thrombotic composite end point, which was defined as a composite of cardiac death, nonfatal myocardial infarction, ischemic stroke, readmission due to acute coronary syndrome, and definite or probable stent thrombosis; and any bleeding, which was defined as Bleeding Academic Research Consortium type &#8805;2 bleeding. The individual components of the primary and thrombotic composite end point, revascularization, and minor gastrointestinal complication were also analyzed as secondary end points at 24 months. The cause of death was evaluated using the medical record classified by the <italic toggle="yes">International Classification of Disease</italic>, <italic toggle="yes">Tenth Revision</italic> (<italic toggle="yes">ICD&#8208;10</italic>). To minimize potential bias by open&#8208;labeled study design, all clinical events were primarily assessed by the investigator and additionally adjudicated by the independent, blinded, and centralized clinical event committee.</p></sec><sec id="jah310075-sec-0011"><title>Renal Function Assessment</title><p>Laboratory results collected from the screening date until randomization were used in this analysis. The estimated glomerular filtration rate (eGFR) was calculated by using the Chronic Kidney Disease Epidemiology Collaboration equation, and patients without creatinine values were excluded from this analysis. CKD was defined having an eGFR &lt;60&#8201;mL/min per 1.73 m<sup>2</sup>, and patients were classified into 3 groups according to the severity of renal dysfunction (normal renal function group, eGFR &#8805;90&#8201;mL/min per 1.73&#8201;m<sup>2</sup>; mild renal dysfunction group, eGFR 60&#8211;90&#8201;mL/min per 1.73&#8201;m<sup>2</sup>; moderate to severe renal dysfunction group, eGFR &lt;60&#8201;mL/min per 1.73&#8201;m<sup>2</sup>).</p></sec><sec id="jah310075-sec-0012"><title>Statistical Analysis</title><p>All clinical events were assessed in the intention&#8208;to&#8208;treat population. Baseline characteristics were evaluated according to the CKD status and treatment arm. They were expressed as mean&#177;SD for continuous variables and absolute count (percentage) for categorical variables. Independent <italic toggle="yes">t</italic> tests were used to compare the continuous variables, and categorical variables were compared by the &#967;<sup>2</sup> or Fisher exact test, as appropriate. Cumulative incidence rates of primary and secondary end points were estimated using the Kaplan&#8211;Meier method, and differences between groups were examined by log&#8208;rank test. A univariable Cox proportional hazards model was used to assess the effect of treatment arm on clinical outcomes according to the presence of CKD. An interaction test was performed to evaluate the differences in treatment effect of antiplatelet agents according to the renal function via introduction of interaction terms between randomized arm assignment and CKD status. A multivariable Cox proportional hazards model was used to assess the effect of renal function on clinical outcomes with adjustment for clinical and procedural characteristics (antiplatelet agent, age, sex, diabetes, hypertension, dyslipidemia, current smoker, history of myocardial infarction, extent of coronary artery disease, presence of left main disease, and the presence of bifurcation). Per&#8208;protocol analyses were conducted as a sensitivity analysis. Using the conventional frequentist analysis, we examined whether the treatment effect of clopidogrel differed according to renal function. To calculate the probability that clopidogrel was superior to aspirin in each renal function group, Bayesian analysis was conducted using JAGS through the rjags package (version 4&#8211;15) in R version 4.3.0 (R Foundation for Statistical Computing, Vienna, Austria)<xref rid="jah310075-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> as another sensitivity analysis. Superiority was defined as a relative risk of clopidogrel over aspirin under the posterior distribution being &lt;1.0. Due to the lack of a previous direct comparison study between aspirin and clopidogrel as chronic maintenance monotherapy after PCI, we made no prior assumptions that one antiplatelet regime was likely to have better outcomes than the other. The 95% highest posterior density interval was selected as a 95% credible interval. All <italic toggle="yes">P</italic> values were 2&#8208;sided, and statistical significance was defined as <italic toggle="yes">P</italic>&lt;0.05. The statistical analysis was performed using R version 4.3.0.</p></sec></sec><sec sec-type="results" id="jah310075-sec-0013"><title>RESULTS</title><sec id="jah310075-sec-0014"><title>Patient Characteristics</title><p>Among 5438 patients enrolled in the HOST&#8208;EXAM trial from March 26, 2014, to May 29, 2018, full data to calculate the eGFR were available in 4844 patients (Figures&#160;<xref rid="jah310075-supitem-0001" ref-type="supplementary-material">S1</xref>). The mean eGFR in the entire population was 89.4&#177;19.5&#8201;mL/min per 1.73&#8201;m<sup>2</sup>, and 508 (10.5%) patients had CKD (defined as eGFR &lt;60&#8201;mL/min per 1.73&#8201;m<sup>2</sup>). The mean eGFR was 44.4&#177;14.6&#8201;mL/min per 1.73&#8201;m<sup>2</sup> and 89.9&#177;13.6&#8201;mL/min per 1.73 m<sup>2</sup> in the CKD and non&#8208;CKD groups respectively. Baseline characteristics according to the presence of CKD are presented in Table&#160;<xref rid="jah310075-supitem-0001" ref-type="supplementary-material">S1</xref>. Patients with CKD were older and more likely to be women, to be a current smoker, and to have a higher prevalence of various comorbidities including diabetes, insulin&#8208;dependent diabetes, and hypertension. Patients with CKD were likely to have a history of cardiovascular accident, left main disease, and multivessel disease. The baseline characteristics according to the randomized antiplatelet treatment within the CKD and non&#8208;CKD groups are presented in Table&#160;<xref rid="jah310075-tbl-0001" ref-type="table">1</xref>. The baseline characteristics were well balanced between the clopidogrel and aspirin groups with no significant differences.</p><table-wrap position="float" id="jah310075-tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>Baseline Patient Characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">CKD</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">P</italic> value</th><th align="left" colspan="2" rowspan="1">Non&#8208;CKD</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">P</italic> value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Aspirin (n=244)</th><th align="left" rowspan="1" colspan="1">Clopidogrel (n=264)</th><th align="left" rowspan="1" colspan="1">Aspirin (n=2174)</th><th align="left" rowspan="1" colspan="1">Clopidogrel (n=2162)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">71.9&#177;9.3</td><td align="left" rowspan="1" colspan="1">71.9&#177;9.3</td><td align="left" rowspan="1" colspan="1">0.994</td><td align="left" rowspan="1" colspan="1">62.3&#177;10.3</td><td align="left" rowspan="1" colspan="1">62.4&#177;10.3</td><td align="left" rowspan="1" colspan="1">0.690</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex, n (%)</td><td align="left" rowspan="1" colspan="1">139 (57.0)</td><td align="left" rowspan="1" colspan="1">149 (56.4)</td><td align="left" rowspan="1" colspan="1">0.905</td><td align="left" rowspan="1" colspan="1">1670 (76.8)</td><td align="left" rowspan="1" colspan="1">1668 (77.2)</td><td align="left" rowspan="1" colspan="1">0.794</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes, n (%)</td><td align="left" rowspan="1" colspan="1">142 (58.2)</td><td align="left" rowspan="1" colspan="1">137 (51.9)</td><td align="left" rowspan="1" colspan="1">0.154</td><td align="left" rowspan="1" colspan="1">700 (32.2)</td><td align="left" rowspan="1" colspan="1">706 (32.7)</td><td align="left" rowspan="1" colspan="1">0.748</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin&#8208;dependent diabetes, n (%)</td><td align="left" rowspan="1" colspan="1">27 (11.1)</td><td align="left" rowspan="1" colspan="1">21 (8.0)</td><td align="left" rowspan="1" colspan="1">0.231</td><td align="left" rowspan="1" colspan="1">33 (1.5)</td><td align="left" rowspan="1" colspan="1">30 (1.4)</td><td align="left" rowspan="1" colspan="1">0.720</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n (%)</td><td align="left" rowspan="1" colspan="1">199 (81.6)</td><td align="left" rowspan="1" colspan="1">205 (77.7)</td><td align="left" rowspan="1" colspan="1">0.276</td><td align="left" rowspan="1" colspan="1">1289 (59.3)</td><td align="left" rowspan="1" colspan="1">1285 (59.4)</td><td align="left" rowspan="1" colspan="1">0.923</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia, n (%)</td><td align="left" rowspan="1" colspan="1">175 (71.7)</td><td align="left" rowspan="1" colspan="1">198 (75.0)</td><td align="left" rowspan="1" colspan="1">0.403</td><td align="left" rowspan="1" colspan="1">1517 (69.8)</td><td align="left" rowspan="1" colspan="1">1518 (70.2)</td><td align="left" rowspan="1" colspan="1">0.755</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker, n (%)</td><td align="left" rowspan="1" colspan="1">26 (10.7)</td><td align="left" rowspan="1" colspan="1">33 (12.5)</td><td align="left" rowspan="1" colspan="1">0.517</td><td align="left" rowspan="1" colspan="1">503 (23.1)</td><td align="left" rowspan="1" colspan="1">453 (21.0)</td><td align="left" rowspan="1" colspan="1">0.083</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous myocardial infarction, n (%)</td><td align="left" rowspan="1" colspan="1">39 (16.0)</td><td align="left" rowspan="1" colspan="1">46 (17.4)</td><td align="left" rowspan="1" colspan="1">0.664</td><td align="left" rowspan="1" colspan="1">365 (16.8)</td><td align="left" rowspan="1" colspan="1">365 (16.9)</td><td align="left" rowspan="1" colspan="1">0.935</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous cardiovascular accident, n (%)</td><td align="left" rowspan="1" colspan="1">23 (9.4)</td><td align="left" rowspan="1" colspan="1">21 (8.0)</td><td align="left" rowspan="1" colspan="1">0.556</td><td align="left" rowspan="1" colspan="1">101 (4.6)</td><td align="left" rowspan="1" colspan="1">84 (3.9)</td><td align="left" rowspan="1" colspan="1">0.215</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical indication of PCI, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.781</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.686</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Silent ischemia</td><td align="left" rowspan="1" colspan="1">8 (3.3)</td><td align="left" rowspan="1" colspan="1">5 (1.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">59 (2.7)</td><td align="left" rowspan="1" colspan="1">45 (2.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stable angina</td><td align="left" rowspan="1" colspan="1">69 (28.3)</td><td align="left" rowspan="1" colspan="1">70 (26.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">540 (24.8)</td><td align="left" rowspan="1" colspan="1">549 (25.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Unstable angina</td><td align="left" rowspan="1" colspan="1">84 (34.4)</td><td align="left" rowspan="1" colspan="1">102 (38.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">756 (34.8)</td><td align="left" rowspan="1" colspan="1">757 (35.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NSTEMI</td><td align="left" rowspan="1" colspan="1">48 (19.7)</td><td align="left" rowspan="1" colspan="1">50 (18.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">422 (19.4)</td><td align="left" rowspan="1" colspan="1">429 (19.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">STEMI</td><td align="left" rowspan="1" colspan="1">35 (14.3)</td><td align="left" rowspan="1" colspan="1">37 (14.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">397 (18.3)</td><td align="left" rowspan="1" colspan="1">382 (17.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">Laboratory results</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Creatinine, mg/dL</td><td align="left" rowspan="1" colspan="1">1.9&#177;1.9</td><td align="left" rowspan="1" colspan="1">2.0&#177;1.9</td><td align="left" rowspan="1" colspan="1">0.763</td><td align="left" rowspan="1" colspan="1">0.9&#177;0.2</td><td align="left" rowspan="1" colspan="1">0.9&#177;0.2</td><td align="left" rowspan="1" colspan="1">0.383</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">eGFR, mL/min per 1.73&#8201;m<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">44.8&#177;14.2</td><td align="left" rowspan="1" colspan="1">44.0&#177;14.9</td><td align="left" rowspan="1" colspan="1">0.517</td><td align="left" rowspan="1" colspan="1">89.7&#177;13.6</td><td align="left" rowspan="1" colspan="1">90.0&#177;13.6</td><td align="left" rowspan="1" colspan="1">0.370</td></tr><tr><td align="left" rowspan="1" colspan="1">Days from PCI to randomization</td><td align="left" rowspan="1" colspan="1">389.3&#177;71.2</td><td align="left" rowspan="1" colspan="1">386.5&#177;66.9</td><td align="left" rowspan="1" colspan="1">0.652</td><td align="left" rowspan="1" colspan="1">389.3&#177;65.0</td><td align="left" rowspan="1" colspan="1">390.5&#177;67.4</td><td align="left" rowspan="1" colspan="1">0.569</td></tr><tr><td align="left" rowspan="1" colspan="1">DAPT at the randomization, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.120</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.398</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin plus clopidogrel</td><td align="left" rowspan="1" colspan="1">214 (87.7)</td><td align="left" rowspan="1" colspan="1">224 (84.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1721 (79.2)</td><td align="left" rowspan="1" colspan="1">1733 (80.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin plus ticagrelor</td><td align="left" rowspan="1" colspan="1">24 (9.8)</td><td align="left" rowspan="1" colspan="1">22 (8.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">223 (10.3)</td><td align="left" rowspan="1" colspan="1">233 (10.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin plus prasugrel</td><td align="left" rowspan="1" colspan="1">4 (1.6)</td><td align="left" rowspan="1" colspan="1">14 (5.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">220 (10.1)</td><td align="left" rowspan="1" colspan="1">187 (8.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin plus clopidogrel plus cilostazol</td><td align="left" rowspan="1" colspan="1">2 (0.8)</td><td align="left" rowspan="1" colspan="1">4 (1.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10 (0.5)</td><td align="left" rowspan="1" colspan="1">9 (0.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">Angiographic data per patient</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Extent of CAD</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.644</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.816</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">1&#8208;vessel disease, n (%)</td><td align="left" rowspan="1" colspan="1">85 (35.0)</td><td align="left" rowspan="1" colspan="1">100 (37.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1123 (51.7)</td><td align="left" rowspan="1" colspan="1">1112 (51.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2&#8208;vessel disease, n (%)</td><td align="left" rowspan="1" colspan="1">81 (33.3)</td><td align="left" rowspan="1" colspan="1">90 (34.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">666 (30.6)</td><td align="left" rowspan="1" colspan="1">679 (31.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">3&#8208;vessel disease, n (%)</td><td align="left" rowspan="1" colspan="1">77 (31.7)</td><td align="left" rowspan="1" colspan="1">74 (28.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">385 (17.7)</td><td align="left" rowspan="1" colspan="1">371 (17.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Left main disease, n (%)</td><td align="left" rowspan="1" colspan="1">16 (6.6)</td><td align="left" rowspan="1" colspan="1">21 (8.0)</td><td align="left" rowspan="1" colspan="1">0.545</td><td align="left" rowspan="1" colspan="1">96 (4.4)</td><td align="left" rowspan="1" colspan="1">110 (5.1)</td><td align="left" rowspan="1" colspan="1">0.298</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multivessel disease, n (%)</td><td align="left" rowspan="1" colspan="1">158 (65.0)</td><td align="left" rowspan="1" colspan="1">164 (62.1)</td><td align="left" rowspan="1" colspan="1">0.498</td><td align="left" rowspan="1" colspan="1">1051 (48.3)</td><td align="left" rowspan="1" colspan="1">1050 (48.6)</td><td align="left" rowspan="1" colspan="1">0.884</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bifurcation, n (%)</td><td align="left" rowspan="1" colspan="1">26 (10.7)</td><td align="left" rowspan="1" colspan="1">32 (12.1)</td><td align="left" rowspan="1" colspan="1">0.604</td><td align="left" rowspan="1" colspan="1">235 (10.8)</td><td align="left" rowspan="1" colspan="1">226 (10.5)</td><td align="left" rowspan="1" colspan="1">0.704</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of treated lesions</td><td align="left" rowspan="1" colspan="1">1.4&#177;0.7</td><td align="left" rowspan="1" colspan="1">1.4&#177;0.6</td><td align="left" rowspan="1" colspan="1">0.475</td><td align="left" rowspan="1" colspan="1">1.3&#177;0.6</td><td align="left" rowspan="1" colspan="1">1.3&#177;0.6</td><td align="left" rowspan="1" colspan="1">0.538</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean diameter of implanted stents, mm</td><td align="left" rowspan="1" colspan="1">3.0&#177;0.4</td><td align="left" rowspan="1" colspan="1">3.0&#177;0.4</td><td align="left" rowspan="1" colspan="1">0.867</td><td align="left" rowspan="1" colspan="1">3.1&#177;0.4</td><td align="left" rowspan="1" colspan="1">3.1&#177;0.4</td><td align="left" rowspan="1" colspan="1">0.894</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Minimum diameter of implanted stents, mm</td><td align="left" rowspan="1" colspan="1">2.9&#177;0.4</td><td align="left" rowspan="1" colspan="1">2.9&#177;0.4</td><td align="left" rowspan="1" colspan="1">0.676</td><td align="left" rowspan="1" colspan="1">3.0&#177;0.5</td><td align="left" rowspan="1" colspan="1">3.0&#177;0.5</td><td align="left" rowspan="1" colspan="1">0.747</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total length of implanted stents, mm</td><td align="left" rowspan="1" colspan="1">40.5&#177;26.8</td><td align="left" rowspan="1" colspan="1">39.8&#177;28.0</td><td align="left" rowspan="1" colspan="1">0.793</td><td align="left" rowspan="1" colspan="1">34.9&#177;22.8</td><td align="left" rowspan="1" colspan="1">35.5&#177;23.7</td><td align="left" rowspan="1" colspan="1">0.394</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total number of implanted stents</td><td align="left" rowspan="1" colspan="1">1.6&#177;1.0</td><td align="left" rowspan="1" colspan="1">1.6&#177;1.0</td><td align="left" rowspan="1" colspan="1">0.816</td><td align="left" rowspan="1" colspan="1">1.4&#177;0.8</td><td align="left" rowspan="1" colspan="1">1.5&#177;0.8</td><td align="left" rowspan="1" colspan="1">0.324</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Generation of DES, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.878</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.639</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">First&#8208;generation DES</td><td align="left" rowspan="1" colspan="1">2 (0.8)</td><td align="left" rowspan="1" colspan="1">2 (0.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">42 (1.9)</td><td align="left" rowspan="1" colspan="1">47 (2.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Second&#8208;generation DES</td><td align="left" rowspan="1" colspan="1">239 (98.0)</td><td align="left" rowspan="1" colspan="1">260 (98.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2111 (97.1)</td><td align="left" rowspan="1" colspan="1">2089 (96.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Unknown generation</td><td align="left" rowspan="1" colspan="1">3 (1.2)</td><td align="left" rowspan="1" colspan="1">2 (0.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21 (1.0)</td><td align="left" rowspan="1" colspan="1">26 (1.2)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="jah310075-ntgp-0002"><fn id="jah310075-note-0006"><p>CAD indicates coronary artery disease; CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; DES, drug&#8208;eluting stent; eGFR, estimated glomerular filtration rate; NSTEMI, non&#8211;ST&#8208;segment&#8211;elevation myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, ST&#8208;segment&#8211;elevation myocardial infarction.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah310075-sec-0015"><title>Clinical Outcomes According to Renal Function</title><p>During the study period of 24&#8201;months, the cumulative incidence of the primary end point was significantly higher in the CKD group compared with the non&#8208;CKD group (11.7% versus 6.0%; hazard ratio [HR], 2.01 [95% CI, 1.51&#8211;2.67; <italic toggle="yes">P</italic>&lt;0.001; log&#8208;rank]; <italic toggle="yes">P</italic>&lt;0.001; Figure&#160;<xref rid="jah310075-fig-0001" ref-type="fig">1A</xref>). CKD was also associated with a higher risk of the thrombotic composite end point (HR, 1.74 [95% CI, 1.21&#8211;2.50]; <italic toggle="yes">P</italic>=0.003; log&#8208;rank <italic toggle="yes">P</italic>=0.002; Figure&#160;<xref rid="jah310075-fig-0001" ref-type="fig">1B</xref>), any bleeding (HR, 2.82 [95% CI, 1.88&#8211;4.22]; <italic toggle="yes">P</italic>&lt;0.001; log&#8208;rank <italic toggle="yes">P</italic>&lt;&#8201;0.001; Figure&#160;<xref rid="jah310075-fig-0001" ref-type="fig">1C</xref>), all&#8208;cause death (HR, 3.99 [95% CI, 2.44&#8211;6.53]; <italic toggle="yes">P</italic>&lt;0.001), and cardiac death (HR, 7.47 [95% CI, 3.35&#8211;16.68]; <italic toggle="yes">P</italic>&lt;0.001). After adjustment for differences in clinical characteristics, results were similar and consistent with that of the univariable analysis (Table&#160;<xref rid="jah310075-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><fig position="float" fig-type="Figure" id="jah310075-fig-0001" orientation="portrait"><label>Figure 1</label><caption><title>Effects of chronic kidney disease on clinical outcomes.</title><p>The cumulative incidences of primary composite end point (<bold>A</bold>), thrombotic composite end point (<bold>B</bold>), and any bleeding (<bold>C</bold>) were compared according to the chronic kidney disease. CKD indicates chronic kidney disease; and HR, hazard ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JAH3-13-e035269-g003.jpg"/></fig><p>When patients were divided into 3 groups according to renal function, 2353 (48.6%) were in the normal renal function group (eGFR &#8805;90&#8201;mL/min per 1.73&#8201;m<sup>2</sup>), 1983 (40.9%) were in the mild renal dysfunction group (eGFR 60&#8211;90&#8201;mL/min per 1.73&#8201;m<sup>2</sup>), and 508 (10.5%) were in the moderate to severe renal dysfunction group (eGFR &lt;60&#8201;mL/min per 1.73&#8201;m<sup>2</sup>). There was an increase in clinical events as the renal function deteriorated (primary end point: 5.3% versus 6.9% versus 11.7%, <italic toggle="yes">P</italic> for trend&lt;0.001; thrombotic end point: 3.9% versus 4.5% versus 7.1%, <italic toggle="yes">P</italic> for trend=0.008; any bleeding: 2.1% versus 2.6% versus 6.4%, <italic toggle="yes">P</italic> for trend&lt;0.001; Figure&#160;<xref rid="jah310075-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><p>The association between continuous eGFR values and the risk of clinical events is shown in Figure&#160;<xref rid="jah310075-supitem-0001" ref-type="supplementary-material">S3</xref>. The risk of clinical events significantly increased as eGFR decreased (adjusted HR for the primary end point per 10&#8201;mL/min per 1.73&#8201;m<sup>2</sup> decrease in eGFR: 1.09 [95% CI, 1.03&#8211;1.16]; adjusted HR for the thrombotic end point per 10&#8201;mL/min per 1.73&#8201;m<sup>2</sup> decrease in eGFR: 1.08 [95% CI, 1.01&#8211;1.17]; adjusted HR for any bleeding per 10&#8201;mL/min per 1.73&#8201;m<sup>2</sup> decrease in eGFR: 1.12 [95% CI, 1.03&#8211;1.23]).</p></sec><sec id="jah310075-sec-0016"><title>Clinical Outcomes According to the Antiplatelet Strategy in the <styled-content style="fixed-case" toggle="no">CKD</styled-content> and Non&#8208;<styled-content style="fixed-case" toggle="no">CKD</styled-content> Groups</title><p>Within the CKD group, the primary end point occurred in 13.4% (32 patients) in the aspirin arm and 10.1% (26 patients) in the clopidogrel arm (HR, 0.74 [95% CI, 0.44&#8211;1.25]; <italic toggle="yes">P</italic>=0.264). In the non&#8208;CKD group, the incidence of the primary end point was 7.0% and 5.1% in the aspirin and clopidogrel arms, respectively (HR, 0.71 [95% CI, 0.56&#8211;0.91]; <italic toggle="yes">P</italic>=0.007). The number needed to treat for clopidogrel over aspirin to prevent 1 primary end point was 33 for the CKD group and 50 for the non&#8208;CKD group. There was no significant interaction between the treatment effect and the presence of CKD (<italic toggle="yes">P</italic> for interaction=0.889; Figure&#160;<xref rid="jah310075-fig-0002" ref-type="fig">2A</xref>). The results were similar for the thrombotic end point (CKD group: HR, 0.69 [95% CI, 0.35&#8211;1.34]; <italic toggle="yes">P</italic>=0.269; non&#8208;CKD group: HR, 0.67 [95% CI, 0.50&#8211;0.91]; <italic toggle="yes">P</italic>=0.010, <italic toggle="yes">P</italic> for interaction=0.963; Figure&#160;<xref rid="jah310075-fig-0002" ref-type="fig">2B</xref>) and any bleeding (CKD group: HR, 0.77 [95% CI, 0.38&#8211;1.56]; <italic toggle="yes">P</italic>=0.466; non&#8208;CKD group: HR, 0.60 [95% CI, 0.40&#8211;0.90]; <italic toggle="yes">P</italic>=0.014; <italic toggle="yes">P</italic> for interaction=0.548; Figure&#160;<xref rid="jah310075-fig-0002" ref-type="fig">2C</xref>). No significant interactions were found between CKD status and treatment effects of any of the other outcomes (all <italic toggle="yes">P</italic> for interaction&gt;0.10; Table&#160;<xref rid="jah310075-tbl-0002" ref-type="table">2</xref>). The per&#8208;protocol analyses yielded similar results to the intention&#8208;to&#8208;treat analyses for the primary end point and the secondary end points (Table&#160;<xref rid="jah310075-supitem-0001" ref-type="supplementary-material">S3</xref>).</p><fig position="float" fig-type="Figure" id="jah310075-fig-0002" orientation="portrait"><label>Figure 2</label><caption><title>Effects of antiplatelet regimen on clinical outcomes according to CKD status.</title><p>The cumulative incidences of primary composite end point (<bold>A</bold>), thrombotic composite end point (<bold>B</bold>), and any bleeding (<bold>C</bold>) were compared according to antiplatelet regimen in patients with CKD and without CKD. CKD indicates chronic kidney disease; and HR, hazard ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="JAH3-13-e035269-g001.jpg"/></fig><table-wrap position="float" id="jah310075-tbl-0002" content-type="Table" orientation="portrait"><label>Table 2</label><caption><p>Clinical Outcomes in Relation to CKD Status and the Randomized Antiplatelet Agents</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="4" rowspan="1">CKD (N=508)</th><th align="left" colspan="4" rowspan="1">Non&#8208;CKD (N=4336)</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">P</italic> for interaction</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Aspirin, n (%) (n=244)</th><th align="left" rowspan="1" colspan="1">Clopidogrel, n (%) (n=264)</th><th align="left" rowspan="1" colspan="1">HR (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th><th align="left" rowspan="1" colspan="1">Aspirin, n (%) (n=2174)</th><th align="left" rowspan="1" colspan="1">Clopidogrel, n (%) (n=2162)</th><th align="left" rowspan="1" colspan="1">HR (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Primary composite end point</td><td align="left" rowspan="1" colspan="1">32 (13.4)</td><td align="left" rowspan="1" colspan="1">26 (10.1)</td><td align="left" rowspan="1" colspan="1">0.74 (0.44&#8211;1.25)</td><td align="left" rowspan="1" colspan="1">0.264</td><td align="left" rowspan="1" colspan="1">151 (7.0)</td><td align="left" rowspan="1" colspan="1">108 (5.1)</td><td align="left" rowspan="1" colspan="1">0.71 (0.56&#8211;0.91)</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">0.889</td></tr><tr><td align="left" rowspan="1" colspan="1">Thrombotic composite end point</td><td align="left" rowspan="1" colspan="1">20 (8.5)</td><td align="left" rowspan="1" colspan="1">15 (5.9)</td><td align="left" rowspan="1" colspan="1">0.69 (0.35&#8211;1.34)</td><td align="left" rowspan="1" colspan="1">0.269</td><td align="left" rowspan="1" colspan="1">107 (5.0)</td><td align="left" rowspan="1" colspan="1">72 (3.4)</td><td align="left" rowspan="1" colspan="1">0.67 (0.50&#8211;0.91)</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">0.963</td></tr><tr><td align="left" rowspan="1" colspan="1">Any bleeding (BARC type &#8805;2)</td><td align="left" rowspan="1" colspan="1">17 (7.2)</td><td align="left" rowspan="1" colspan="1">14 (5.5)</td><td align="left" rowspan="1" colspan="1">0.77 (0.38&#8211;1.56)</td><td align="left" rowspan="1" colspan="1">0.466</td><td align="left" rowspan="1" colspan="1">62 (2.9)</td><td align="left" rowspan="1" colspan="1">37 (1.7)</td><td align="left" rowspan="1" colspan="1">0.60 (0.40&#8211;0.90)</td><td align="left" rowspan="1" colspan="1">0.014</td><td align="left" rowspan="1" colspan="1">0.548</td></tr><tr><td align="left" rowspan="1" colspan="1">All&#8208;cause death</td><td align="left" rowspan="1" colspan="1">10 (4.2)</td><td align="left" rowspan="1" colspan="1">13 (5.1)</td><td align="left" rowspan="1" colspan="1">1.21 (0.53&#8211;2.77)</td><td align="left" rowspan="1" colspan="1">0.644</td><td align="left" rowspan="1" colspan="1">22 (1.0)</td><td align="left" rowspan="1" colspan="1">29 (1.4)</td><td align="left" rowspan="1" colspan="1">1.33 (0.76&#8211;2.32)</td><td align="left" rowspan="1" colspan="1">0.313</td><td align="left" rowspan="1" colspan="1">0.862</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac death</td><td align="left" rowspan="1" colspan="1">4 (1.7)</td><td align="left" rowspan="1" colspan="1">7 (2.8)</td><td align="left" rowspan="1" colspan="1">1.63 (0.48&#8211;5.57)</td><td align="left" rowspan="1" colspan="1">0.435</td><td align="left" rowspan="1" colspan="1">7 (0.3)</td><td align="left" rowspan="1" colspan="1">6 (0.3)</td><td align="left" rowspan="1" colspan="1">0.87 (0.29&#8211;2.57)</td><td align="left" rowspan="1" colspan="1">0.794</td><td align="left" rowspan="1" colspan="1">0.447</td></tr><tr><td align="left" rowspan="1" colspan="1">Noncardiac death</td><td align="left" rowspan="1" colspan="1">6 (2.6)</td><td align="left" rowspan="1" colspan="1">6 (2.3)</td><td align="left" rowspan="1" colspan="1">0.94 (0.30&#8211;2.90)</td><td align="left" rowspan="1" colspan="1">0.909</td><td align="left" rowspan="1" colspan="1">15 (0.7)</td><td align="left" rowspan="1" colspan="1">23 (1.1)</td><td align="left" rowspan="1" colspan="1">1.55 (0.81&#8211;2.97)</td><td align="left" rowspan="1" colspan="1">0.188</td><td align="left" rowspan="1" colspan="1">0.452</td></tr><tr><td align="left" rowspan="1" colspan="1">Nonfatal myocardial infarction</td><td align="left" rowspan="1" colspan="1">2 (0.8)</td><td align="left" rowspan="1" colspan="1">1 (0.4)</td><td align="left" rowspan="1" colspan="1">0.46 (0.04&#8211;5.11)</td><td align="left" rowspan="1" colspan="1">0.530</td><td align="left" rowspan="1" colspan="1">24 (1.1)</td><td align="left" rowspan="1" colspan="1">15 (0.7)</td><td align="left" rowspan="1" colspan="1">0.63 (0.33&#8211;1.2)</td><td align="left" rowspan="1" colspan="1">0.159</td><td align="left" rowspan="1" colspan="1">0.812</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1">7 (3)</td><td align="left" rowspan="1" colspan="1">2 (0.8)</td><td align="left" rowspan="1" colspan="1">0.26 (0.05&#8211;1.27)</td><td align="left" rowspan="1" colspan="1">0.097</td><td align="left" rowspan="1" colspan="1">28 (1.3)</td><td align="left" rowspan="1" colspan="1">12 (0.6)</td><td align="left" rowspan="1" colspan="1">0.43 (0.22&#8211;0.85)</td><td align="left" rowspan="1" colspan="1">0.015</td><td align="left" rowspan="1" colspan="1">0.576</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic stroke</td><td align="left" rowspan="1" colspan="1">4 (1.7)</td><td align="left" rowspan="1" colspan="1">2 (0.8)</td><td align="left" rowspan="1" colspan="1">0.46 (0.08&#8211;2.53)</td><td align="left" rowspan="1" colspan="1">0.374</td><td align="left" rowspan="1" colspan="1">17 (0.8)</td><td align="left" rowspan="1" colspan="1">9 (0.4)</td><td align="left" rowspan="1" colspan="1">0.53 (0.24&#8211;1.20)</td><td align="left" rowspan="1" colspan="1">0.127</td><td align="left" rowspan="1" colspan="1">0.885</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic stroke</td><td align="left" rowspan="1" colspan="1">3 (1.3)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">11 (0.5)</td><td align="left" rowspan="1" colspan="1">3 (0.1)</td><td align="left" rowspan="1" colspan="1">0.27 (0.08&#8211;0.99)</td><td align="left" rowspan="1" colspan="1">0.047</td><td align="left" rowspan="1" colspan="1">0.997</td></tr><tr><td align="left" rowspan="1" colspan="1">Readmission due to ACS</td><td align="left" rowspan="1" colspan="1">13 (5.5)</td><td align="left" rowspan="1" colspan="1">6 (2.4)</td><td align="left" rowspan="1" colspan="1">0.43 (0.16&#8211;1.12)</td><td align="left" rowspan="1" colspan="1">0.083</td><td align="left" rowspan="1" colspan="1">84 (3.9)</td><td align="left" rowspan="1" colspan="1">57 (2.7)</td><td align="left" rowspan="1" colspan="1">0.68 (0.49&#8211;0.95)</td><td align="left" rowspan="1" colspan="1">0.025</td><td align="left" rowspan="1" colspan="1">0.368</td></tr><tr><td align="left" rowspan="1" colspan="1">Major bleeding (BARC type &#8805;3)</td><td align="left" rowspan="1" colspan="1">9 (3.8)</td><td align="left" rowspan="1" colspan="1">8 (3.2)</td><td align="left" rowspan="1" colspan="1">0.83 (0.32&#8211;2.16)</td><td align="left" rowspan="1" colspan="1">0.709</td><td align="left" rowspan="1" colspan="1">39 (1.8)</td><td align="left" rowspan="1" colspan="1">20 (0.9)</td><td align="left" rowspan="1" colspan="1">0.52 (0.30&#8211;0.88)</td><td align="left" rowspan="1" colspan="1">0.016</td><td align="left" rowspan="1" colspan="1">0.388</td></tr><tr><td align="left" rowspan="1" colspan="1">Any revascularization</td><td align="left" rowspan="1" colspan="1">4 (1.7)</td><td align="left" rowspan="1" colspan="1">6 (2.4)</td><td align="left" rowspan="1" colspan="1">1.40 (0.39&#8211;4.95)</td><td align="left" rowspan="1" colspan="1">0.604</td><td align="left" rowspan="1" colspan="1">57 (2.7)</td><td align="left" rowspan="1" colspan="1">44 (2.1)</td><td align="left" rowspan="1" colspan="1">0.78 (0.52&#8211;1.15)</td><td align="left" rowspan="1" colspan="1">0.208</td><td align="left" rowspan="1" colspan="1">0.380</td></tr><tr><td align="left" rowspan="1" colspan="1">Target&#8208;lesion revascularization</td><td align="left" rowspan="1" colspan="1">1 (0.4)</td><td align="left" rowspan="1" colspan="1">2 (0.8)</td><td align="left" rowspan="1" colspan="1">1.86 (0.17&#8211;20.48)</td><td align="left" rowspan="1" colspan="1">0.613</td><td align="left" rowspan="1" colspan="1">29 (1.4)</td><td align="left" rowspan="1" colspan="1">19 (0.9)</td><td align="left" rowspan="1" colspan="1">0.66 (0.37&#8211;1.18)</td><td align="left" rowspan="1" colspan="1">0.158</td><td align="left" rowspan="1" colspan="1">0.406</td></tr><tr><td align="left" rowspan="1" colspan="1">Target&#8208;vessel revascularization</td><td align="left" rowspan="1" colspan="1">3 (1.3)</td><td align="left" rowspan="1" colspan="1">4 (1.6)</td><td align="left" rowspan="1" colspan="1">1.25 (0.28&#8211;5.56)</td><td align="left" rowspan="1" colspan="1">0.774</td><td align="left" rowspan="1" colspan="1">38 (1.8)</td><td align="left" rowspan="1" colspan="1">29 (1.4)</td><td align="left" rowspan="1" colspan="1">0.77 (0.47&#8211;1.24)</td><td align="left" rowspan="1" colspan="1">0.284</td><td align="left" rowspan="1" colspan="1">0.543</td></tr><tr><td align="left" rowspan="1" colspan="1">Definite or probable stent thrombosis</td><td align="left" rowspan="1" colspan="1">1 (0.4)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">12 (0.6)</td><td align="left" rowspan="1" colspan="1">9 (0.4)</td><td align="left" rowspan="1" colspan="1">0.76 (0.32&#8211;1.80)</td><td align="left" rowspan="1" colspan="1">0.528</td><td align="left" rowspan="1" colspan="1">0.997</td></tr><tr><td align="left" rowspan="1" colspan="1">Any minor gastrointestinal complications</td><td align="left" rowspan="1" colspan="1">30 (12.7)</td><td align="left" rowspan="1" colspan="1">36 (14.1)</td><td align="left" rowspan="1" colspan="1">1.14 (0.70&#8211;1.85)</td><td align="left" rowspan="1" colspan="1">0.605</td><td align="left" rowspan="1" colspan="1">264 (12.3)</td><td align="left" rowspan="1" colspan="1">212 (10.0)</td><td align="left" rowspan="1" colspan="1">0.80 (0.67&#8211;0.96)</td><td align="left" rowspan="1" colspan="1">0.015</td><td align="left" rowspan="1" colspan="1">0.182</td></tr></tbody></table><table-wrap-foot id="jah310075-ntgp-0003"><fn id="jah310075-note-0007"><p>ACS indicates acute coronary syndrome; BARC, Bleeding Academic Research Consortium; CKD, chronic kidney disease; and HR, hazard ratio.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah310075-sec-0017"><title>Treatment Effect and Outcomes According to the Severity of Renal Dysfunction</title><p>The treatment effects of clopidogrel versus aspirin was analyzed according to the degree of renal dysfunction (normal renal function, mild renal dysfunction, and moderate to severe renal dysfunction). There was no significant interaction between the degree of renal dysfunction and the treatment strategy with regard to the primary end point (<italic toggle="yes">P</italic> for interaction=0.570), the thrombotic end point (<italic toggle="yes">P</italic> for interaction=0.978) and any bleeding (<italic toggle="yes">P</italic> for interaction=0.161; Figure&#160;<xref rid="jah310075-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="Figure" id="jah310075-fig-0003" orientation="portrait"><label>Figure 3</label><caption><title>Clinical outcomes according to antiplatelet regimen in the normal renal function, mild renal dysfunction, and moderate to severe renal dysfunction groups.</title><p>The HR for primary composite end point, thrombotic composite end point, and any bleeding were shown according to antiplatelet regimen in the normal renal function, mild renal dysfunction, and moderate to severe renal dysfunction groups. HR indicates hazard ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="JAH3-13-e035269-g002.jpg"/></fig><p>Per Bayesian analysis, the probability that clopidogrel is superior to aspirin for the primary end point was 99% in the normal renal function group (relative risk, 0.67 [95% highest posterior density interval, 0.45&#8211;0.91]), 93% in the mild renal dysfunction group (relative risk, 0.79 [95% highest posterior density interval, 0.54&#8211;1.05]), and 88% in moderate to severe renal dysfunction group (relative risk, 0.78 [95% highest posterior density interval, 0.42&#8211;1.16]). The probability that clopidogrel is superior for the thrombotic end point was 96%, 97%, and 87% in the normal renal function, mild renal dysfunction, and moderate to severe renal dysfunction groups, respectively. That for any bleeding was 100%, 80%, and 78% in the 3 respective groups (Table&#160;<xref rid="jah310075-supitem-0001" ref-type="supplementary-material">S4</xref>).</p></sec></sec><sec sec-type="discussion" id="jah310075-sec-0018"><title>DISCUSSION</title><p>In this post hoc analysis of the HOST&#8208;EXAM trial, we studied whether the beneficial effects of clopidogrel over aspirin during the chronic maintenance monotherapy following PCI is consistent in patients with CKD. Our principal findings are as follows: (1) Patients with CKD have a higher incidence of both thrombotic and bleeding events than those patients without CKD; and (2) there was no difference in the treatment effect of clopidogrel monotherapy according to CKD status and degree of renal function.</p><sec id="jah310075-sec-0019"><title>Clinical Implication of <styled-content style="fixed-case" toggle="no">CKD</styled-content> in Patients Who Underwent <styled-content style="fixed-case" toggle="no">PCI</styled-content>
</title><p>The proportion of patients with CKD undergoing PCI is increasing due to the high prevalence of coronary artery disease in these patients, an aging society, and increasing incidence of comorbidities including diabetes, hypertension, and obesity.<xref rid="jah310075-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310075-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jah310075-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jah310075-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> There are few clinical trials comparing post&#8208;PCI pharmacotherapy in patients with CKD, but several registry studies have shown that CKD is associated with adverse clinical events in such patients.<xref rid="jah310075-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="jah310075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="jah310075-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="jah310075-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="jah310075-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jah310075-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>In the PROMETHEUS (Prasugrel or Clopidogrel in Patients With Acute Coronary Syndromes at High Thrombotic Risk) study, CKD was significantly associated with a higher risk for both major adverse cardiac events and bleeding events at 1 year.<xref rid="jah310075-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Our study showed similar results where CKD was an independent risk factor for not only the primary end point, a composite of both ischemic and bleeding outcomes but also each thrombotic end point and any bleeding events. It is interesting that CKD is a co&#8211;risk factor for both ischemic and bleeding events, which are considered to have opposite characteristics. Among various thrombotic events, CKD was associated with a higher risk of cardiac death and all cause death, which are the most fatal outcomes. In particular, CKD showed a strong association with cardiac death, even after other covariates were adjusted. Also, cardiac death accounted for nearly half of all&#8208;cause deaths (11/23) in patients with CKD, while cardiac death accounted for only about a quarter of all&#8208;cause deaths (13/51) in patients without CKD. These findings are consistent with previous studies. A subgroup analysis of the EVENT (Evaluation of Drug&#8208;Eluting Stents and Ischemic Events) registry assessed 1&#8208;year outcomes following PCI with drug&#8208;eluting stents according to renal function.<xref rid="jah310075-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> In this study, there was an increase in fatal outcomes including cardiac death and myocardial infarction with decreasing creatinine clearance. In another study, the risk of death and myocardial infarction increased with worsening renal function, but the risk of target&#8208;vessel revascularization did not show a significant association with renal function.<xref rid="jah310075-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> In addition, deteriorating renal function was associated with higher risk of adverse clinical events not only when patients were divided into CKD and non&#8208;CKD groups but also when analyzed in 3 groups according to the degree of renal dysfunction (normal, mild, and moderate to severe renal dysfunction) and when analyzed on the basis of continuous eGFR value. Taken together, our results along with data from previous reports suggest that optimal post&#8208;PCI pharmacotherapy may be especially important for patients with impaired renal function.</p></sec><sec id="jah310075-sec-0020"><title>Long&#8208;Term Antiplatelet Strategy in Patients With <styled-content style="fixed-case" toggle="no">CKD</styled-content> Who Underwent <styled-content style="fixed-case" toggle="no">PCI</styled-content>
</title><p>Antiplatelet agents are one of the most important medications to prevent adverse events in patients with coronary artery disease. Since patients who undergo PCI are indicated for lifelong antiplatelet therapy, finding the optimal agent is especially important.<xref rid="jah310075-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Among various antiplatelet agents, aspirin and clopidogrel have been used for a long time in patients with cardiovascular disease risk. However, there was no study comparing the traditionally used aspirin and clopidogrel as proper monotherapy during chronic maintenance period in patients who underwent coronary stenting before HOST&#8208;EXAM trial.<xref rid="jah310075-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Although the CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events) trial showed that clopidogrel was more effective than aspirin in reducing major adverse cardiovascular events in patients with atherosclerotic vascular disease, it did not focus on the patients who underwent PCI and was performed before the era of &#8220;high&#8208;dose, high&#8208;intensity&#8221; statins.<xref rid="jah310075-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> In the HOST&#8208;EXAM trial, the most contemporary trial comparing long&#8208;term maintenance antiplatelet monotherapy in a dedicated PCI population, clopidogrel was superior to aspirin in reducing the risk of both thrombotic and bleeding events. The effect of antiplatelet drugs could be influenced by change in renal function because platelet function and the enzymatic coagulation cascade can be affected by renal function.<xref rid="jah310075-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="jah310075-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="jah310075-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Combined with thrombogenic and bleeding characteristics in patients with CKD, it is difficult to predict the final effect of antiplatelet agents adjusted by the impaired renal function. For example, the CKD substudy of the CREDO (Clopidogrel for the Reduction of Events During Observation) trial showed that clopidogrel reduced the risk of thrombotic events in patients with normal renal function but not in those with mild to moderate CKD.<xref rid="jah310075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Therefore, it is important to study whether the benefits seen in the main trial are consistent and sustained in patients with CKD or those with renal dysfunction.</p><p>In our substudy, the clopidogrel arm had numerically lower rates of adverse outcomes including the primary composite end point, thrombotic composite end point, and any bleeding compared with the aspirin arm in both the CKD and non&#8208;CKD groups. Although the difference did not reach statistical significance, there was no significant interaction between the treatment effect and CKD status for any of the outcomes. These results were similar in the per&#8208;protocol analysis. Furthermore, when patients were divided into 3 groups according to degree of renal dysfunction (eGFR &#8805;90, 60&#8211;90, and &lt;60&#8201;mL/min per 1.73&#8201;m<sup>2</sup>), there was no significant difference in the treatment effects of clopidogrel over aspirin across the 3 groups.</p><p>While our conventional frequentist analysis showed no statistical difference in treatment effects of clopidogrel over aspirin according to renal function, it may be worthwhile to understand to what extent clopidogrel is beneficial in each renal function group. Due to the innate limitations of subgroups analyses, it may be challenging to precisely determine this. However, using a Bayesian analysis, we observed a much greater probability of a lower incidence of clinical events in the clopidogrel arm, even in the subgroup with eGFR &lt;60&#8201;mL/min per 1.73&#8201;m<sup>2</sup>.</p><p>Recently, the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial has demonstrated that dual pathway inhibition with low&#8208;dose rivaroxaban (2.5&#8201;mg twice daily) and aspirin compared with aspirin alone showed better cardiovascular outcomes (a composite of cardiovascular death, stroke, or myocardial infarction) in patients with stable cardiovascular disease at the cost of an increased risk in major bleeding.<xref rid="jah310075-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Our findings of lower bleeding when using clopidogrel over aspirin could open the possibility of dual pathway inhibition using clopidogrel instead of aspirin. Of course, it is unknown how rivaroxaban will interact with clopidogrel, and further studies will be necessary to test whether this could be a feasible option for secondary prevention in patients with high ischemic risk.</p></sec><sec id="jah310075-sec-0021"><title>Limitations</title><p>This study has several limitations. First, the randomization in HOST&#8208;EXAM trial was not stratified by CKD status, and it may cause some imbalance between the randomized groups among patients with CKD. Second, due to the limitation of subgroup analysis, the CKD group was underpowered to draw any definitive conclusions on the superior effect of clopidogrel over aspirin on clinical outcomes. Therefore, our results should be interpreted carefully and considered hypothesis generating at best. Third, we used the baseline renal function to define CKD, and thus any changes in renal function over the study period were not incorporated in the analysis. Fourth, the prognostic value of continuous eGFR in each clopidogrel and aspirin group could not be investigated due to the limited number of patients with CKD. We will require further studies in a dedicated CKD population to determine the optimal chronic maintenance antiplatelet strategy in CKD patients undergoing PCI.</p></sec></sec><sec sec-type="conclusions" id="jah310075-sec-0022"><title>CONCLUSIONS</title><p>In patients indicated for chronic maintenance antiplatelet monotherapy after due duration of dual antiplatelet therapy following PCI, the risk of thrombotic and bleeding events was significantly higher in those with CKD compared with those without CKD. There were no significant differences in the treatment effect of clopidogrel over aspirin according to baseline renal function.</p></sec><sec id="jah310075-sec-0023"><title>Sources of Funding</title><p>The funding source of this study was grants from the Patient&#8208;Centered Clinical Research Coordinating Center (grant number: HI19C0481, HC19C0305). The study funder had no role in the trial design; data collection, analysis, interpretation; or manuscript writing.</p></sec><sec id="jah310075-sec-0024"><title>Disclosures</title><p>Dr K. W. Park reports consultant fees from Shockwave Inc and speaker fees from Daichi Sankyo, Daewoong Pharmaceutical. and HK InnoN Pharmaceuticals outside of the submitted manuscript. The remaining authors have no disclosures to report.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jah310075-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Tables S1&#8211;S4</p><p>Figures&#160;S1&#8211;S3</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JAH3-13-e035269-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah310075-bibl-0001"><title>References</title><ref id="jah310075-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah310075-cit-0001"><string-name name-style="western"><surname>Go</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Chertow</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>McCulloch</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>CY</given-names></string-name>. <article-title>Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>351</volume>:<fpage>1296</fpage>&#8211;<lpage>1305</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa041031</pub-id><pub-id pub-id-type="pmid">15385656</pub-id></mixed-citation></ref><ref id="jah310075-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah310075-cit-0002"><string-name name-style="western"><surname>Matsushita</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>van der Velde</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Astor</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Woodward</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Levey</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>de Jong</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Coresh</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gansevoort</surname><given-names>RT</given-names></string-name>. <article-title>Association of estimated glomerular filtration rate and albuminuria with all&#8208;cause and cardiovascular mortality in general population cohorts: a collaborative meta&#8208;analysis</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>:<fpage>2073</fpage>&#8211;<lpage>2081</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0140-6736(10)60674-5</pub-id><pub-id pub-id-type="pmid">20483451</pub-id><pub-id pub-id-type="pmcid">PMC3993088</pub-id></mixed-citation></ref><ref id="jah310075-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah310075-cit-0003"><string-name name-style="western"><surname>Molnar</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Bota</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Garg</surname><given-names>AX</given-names></string-name>, <string-name name-style="western"><surname>Harel</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lam</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>McArthur</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Nesrallah</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Perl</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sood</surname><given-names>MM</given-names></string-name>. <article-title>The risk of major hemorrhage with CKD</article-title>. <source>J Am Soc Nephrol</source>. <year>2016</year>;<volume>27</volume>:<fpage>2825</fpage>&#8211;<lpage>2832</lpage>. doi: <pub-id pub-id-type="doi">10.1681/asn.2015050535</pub-id><pub-id pub-id-type="pmid">26823554</pub-id><pub-id pub-id-type="pmcid">PMC5004646</pub-id></mixed-citation></ref><ref id="jah310075-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah310075-cit-0004"><string-name name-style="western"><surname>Capodanno</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>. <article-title>Antithrombotic therapy in patients with chronic kidney disease</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>125</volume>:<fpage>2649</fpage>&#8211;<lpage>2661</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.084996</pub-id><pub-id pub-id-type="pmid">22644369</pub-id></mixed-citation></ref><ref id="jah310075-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah310075-cit-0005"><string-name name-style="western"><surname>Koo</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Won</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Rha</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Hur</surname><given-names>SH</given-names></string-name>, et&#160;al. <article-title>Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST&#8208;EXAM): an investigator&#8208;initiated, prospective, randomised, open&#8208;label, multicentre trial</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>397</volume>:<fpage>2487</fpage>&#8211;<lpage>2496</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0140-6736(21)01063-1</pub-id><pub-id pub-id-type="pmid">34010616</pub-id></mixed-citation></ref><ref id="jah310075-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah310075-cit-0006"><string-name name-style="western"><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Koo</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Rha</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Jeon</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Hur</surname><given-names>SH</given-names></string-name>, et&#160;al. <article-title>A randomized clinical trial comparing long&#8208;term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug&#8208;eluting coronary stent implantation: design and rationale of the harmonizing optimal strategy for treatment of coronary artery stenosis&#8208;Extended antiplatelet monotherapy (HOST&#8208;EXAM) trial</article-title>. <source>Am Heart J</source>. <year>2017</year>;<volume>185</volume>:<fpage>17</fpage>&#8211;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ahj.2016.12.001</pub-id><pub-id pub-id-type="pmid">28267471</pub-id></mixed-citation></ref><ref id="jah310075-bib-0007"><label>7</label><mixed-citation publication-type="miscellaneous" id="jah310075-cit-0007"><string-name name-style="western"><surname>Plummer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stukalov</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Denwood</surname><given-names>M</given-names></string-name>. <article-title>Bayesian graphical models using MCMC</article-title>. <year>2023</year> 4&#8211;15.</mixed-citation></ref><ref id="jah310075-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah310075-cit-0008"><string-name name-style="western"><surname>Jha</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Garcia&#8208;Garcia</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Iseki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Naicker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Plattner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Saran</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>AY&#8208;M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>C&#8208;W</given-names></string-name>. <article-title>Chronic kidney disease: global dimension and perspectives</article-title>. <source>Lancet</source>. <year>2013</year>;<volume>382</volume>:<fpage>260</fpage>&#8211;<lpage>272</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0140-6736(13)60687-x</pub-id><pub-id pub-id-type="pmid">23727169</pub-id></mixed-citation></ref><ref id="jah310075-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah310075-cit-0009"><string-name name-style="western"><surname>Cai</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Mukku</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Ahmad</surname><given-names>M</given-names></string-name>. <article-title>Coronary artery disease in patients with chronic kidney disease: a clinical update</article-title>. <source>Curr Cardiol Rev</source>. <year>2013</year>;<volume>9</volume>:<fpage>331</fpage>&#8211;<lpage>339</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1573403x10666140214122234</pub-id><pub-id pub-id-type="pmid">24527682</pub-id><pub-id pub-id-type="pmcid">PMC3941098</pub-id></mixed-citation></ref><ref id="jah310075-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah310075-cit-0010"><string-name name-style="western"><surname>Chan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ivanov</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kotowycz</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Sibbald</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McGeoch</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Crooks</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hatton</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ing</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Daly</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mackie</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Association between drug&#8208;eluting stent type and clinical outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention</article-title>. <source>Can J Cardiol</source>. <year>2014</year>;<volume>30</volume>:<fpage>1170</fpage>&#8211;<lpage>1176</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cjca.2014.04.034</pub-id><pub-id pub-id-type="pmid">25262859</pub-id></mixed-citation></ref><ref id="jah310075-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah310075-cit-0011"><string-name name-style="western"><surname>Bloom</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Dinh</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Noaman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Batchelor</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Reid</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Brennan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lefkovits</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Adverse impact of chronic kidney disease on clinical outcomes following percutaneous coronary intervention</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2021</year>;<volume>97</volume>:<fpage>E801</fpage>&#8211;<lpage>e809</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ccd.29436</pub-id><pub-id pub-id-type="pmid">33325620</pub-id></mixed-citation></ref><ref id="jah310075-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah310075-cit-0012"><string-name name-style="western"><surname>Kaya</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cuneo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hochadel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>J&#252;nger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Stepper</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bramlage</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kuck</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Nienaber</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Senges</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eckardt</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug&#8208;eluting stents</article-title>. <source>Clin Res Cardiol</source>. <year>2011</year>;<volume>100</volume>:<fpage>1103</fpage>&#8211;<lpage>1109</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00392-011-0347-7</pub-id><pub-id pub-id-type="pmid">21912915</pub-id></mixed-citation></ref><ref id="jah310075-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah310075-cit-0013"><string-name name-style="western"><surname>Appleby</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Ivanov</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lavi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mackie</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Horlick</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Ing</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Overgaard</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Seidelin</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>von Harsdorf</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dzav&#237;k</surname><given-names>V</given-names></string-name>. <article-title>The adverse long&#8208;term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug&#8208;eluting stent era</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2009</year>;<volume>2</volume>:<fpage>309</fpage>&#8211;<lpage>316</lpage>. doi: <pub-id pub-id-type="doi">10.1161/circinterventions.108.828954</pub-id><pub-id pub-id-type="pmid">20031733</pub-id></mixed-citation></ref><ref id="jah310075-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah310075-cit-0014"><string-name name-style="western"><surname>Best</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Lennon</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ting</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Rihal</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Berger</surname><given-names>PB</given-names></string-name>. <article-title>The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>39</volume>:<fpage>1113</fpage>&#8211;<lpage>1119</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0735-1097(02)01745-x</pub-id><pub-id pub-id-type="pmid">11923033</pub-id></mixed-citation></ref><ref id="jah310075-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah310075-cit-0015"><string-name name-style="western"><surname>Baber</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Chandrasekhar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sartori</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aquino</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kini</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Kapadia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Weintraub</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Muhlestein</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Faggioni</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the PROMETHEUS study</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2017</year>;<volume>10</volume>:<fpage>2017</fpage>&#8211;<lpage>2025</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2017.02.047</pub-id><pub-id pub-id-type="pmid">28780028</pub-id></mixed-citation></ref><ref id="jah310075-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah310075-cit-0016"><string-name name-style="western"><surname>Latif</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kleiman</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Pencina</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Yen</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Cutlip</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Moliterno</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Nassif</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Saucedo</surname><given-names>JF</given-names></string-name>, et&#160;al. <article-title>In&#8208;hospital and 1&#8208;year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug&#8208;eluting stents: a report from the EVENT (evaluation of drug eluting stents and ischemic events) registry</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2009</year>;<volume>2</volume>:<fpage>37</fpage>&#8211;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2008.06.012</pub-id><pub-id pub-id-type="pmid">19463396</pub-id></mixed-citation></ref><ref id="jah310075-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah310075-cit-0017"><string-name name-style="western"><surname>Neumann</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Sousa&#8208;Uva</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ahlsson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Alfonso</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Banning</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Benedetto</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Byrne</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Collet</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Falk</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Head</surname><given-names>SJ</given-names></string-name>, et&#160;al. <article-title>2018 ESC/EACTS Guidelines on myocardial revascularization</article-title>. <source>Eur Heart J</source>. <year>2019</year>;<volume>40</volume>:<fpage>87</fpage>&#8211;<lpage>165</lpage>. doi: <pub-id pub-id-type="doi">10.1093/eurheartj/ehy394</pub-id><pub-id pub-id-type="pmid">30165437</pub-id></mixed-citation></ref><ref id="jah310075-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah310075-cit-0018"><article-title>A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee</article-title>. <source>Lancet</source>. <year>1996</year>;<volume>348</volume>:<fpage>1329</fpage>&#8211;<lpage>1339</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0140-6736(96)09457-3</pub-id><pub-id pub-id-type="pmid">8918275</pub-id></mixed-citation></ref><ref id="jah310075-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah310075-cit-0019"><string-name name-style="western"><surname>Best</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Steinhubl</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Berger</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Dasgupta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brennan</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Szczech</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Califf</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Topol</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Investigators</surname><given-names>C</given-names></string-name>. <article-title>The efficacy and safety of short&#8208; and long&#8208;term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the clopidogrel for the reduction of events during observation (CREDO) trial</article-title>. <source>Am Heart J</source>. <year>2008</year>;<volume>155</volume>:<fpage>687</fpage>&#8211;<lpage>693</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ahj.2007.10.046</pub-id><pub-id pub-id-type="pmid">18371477</pub-id></mixed-citation></ref><ref id="jah310075-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah310075-cit-0020"><string-name name-style="western"><surname>Eikelboom</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Connolly</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Bosch</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dagenais</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Shestakovska</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Alings</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lonn</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Anand</surname><given-names>SS</given-names></string-name>, et&#160;al. <article-title>Rivaroxaban with or without aspirin in stable cardiovascular disease</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>:<fpage>1319</fpage>&#8211;<lpage>1330</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1709118</pub-id><pub-id pub-id-type="pmid">28844192</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>